Madpatsy

OCU+

[Ocugen @Ocugen]

Hear from CEO @drsmusunuri during the @Piper_Sandler Virtual Ophthalmology Day Fireside Chat as he shares updates on our clinical pipeline, strategic priorities, and vision for advancing transformative gene therapies for patients with retinal diseases.

🔗https://t.co/vHjpcwJthM

[Ocugen @Ocugen]

Early #OCU410ST results show:
✓ 54% reduction in atrophic lesion growth
✓ 100% of treated eyes stabilized or improved
✓ +6 letter gain in visual acuity

Hear from an OCU410ST clinical trial participant: https://t.co/znh5I8UL9R

$OCGN

[Madpatsy @Madpatsy_]

@germanh42341755 @tj_t543210987 Booooom. 😉

[Ocugen @Ocugen]

Honored to join the U.S. @CommerceGov Certified Trade Mission to Singapore with https://t.co/MFNdMesYmg, connecting with investors and industry leaders to advance cross-border collaboration. Looking forward to continuing the conversation globally. @drsmusunuri #TradeMission

[Ocugen @Ocugen]

With the successful completion of enrollment in the GARDian3 Phase 2/3 pivotal trial for Stargardt disease, Ocugen expects to file BLA by mid-2027.

Read more: https://t.co/GdGaVwoRnw

#Stargardt #GeneTherapy #InheritedRetinalDiseases #BlindnessDiseases

[Deebs @DeebsFLA]

Rename one of the Navy ships after Chuck Norris. Not the Cesar Chavez one, because it's just a dry cargo ship. The legend needs a destroyer with his name on it. Get it done, @PeteHegseth

[Ocugen @Ocugen]

Imagine your vision slowly fading. For millions, this is reality. Early detection and routine eye exams are key. This #SaveYourVisionMonth, Ocugen is advancing innovation through our novel modifier gene therapies that addresses major blindness diseases. #EyeHealth #GeneTherapy

[Chief Nerd @TheChiefNerd]

🚨 BREAKING: CDC Data Finds the Flu Vaccine ‘Didn’t Really Work’ This Season

“The vaccine had one of the worst effectiveness rates in more than a decade, only working about 25% of the time.”

[Ocugen @Ocugen]

Ocugen welcomes Paul Staid as EVP of Operations! With 20+ years in biologics & gene therapy operations, he will lead supply chain, manufacturing, quality, and digital strategies and support our transition toward regulatory approvals and commercialization. #BiotechLeadership

[Ocugen @Ocugen]

Ocugen closes 2025 with major milestones: #OCU400 Phase 3 complete for RP, #OCU410ST advancing, positive #OCU410 Phase 2 for #dryAMD, first OCU400 licensing deal, and strengthened leadership. First of three BLA filings ahead! @drsmusunuri #Biotech

Read: https://t.co/tUeJF2yp0q

[Madpatsy @Madpatsy_]

@tj_t543210987 Ocu400 will be fast-tracked. It’s ODD and RMAT. It isn’t submitted yet, so it isn’t updated or in their system. Remember - We assume the data will be good enough to submit. Cart - Horse.

[Ocugen @Ocugen]

Enrollment is now complete for the Phase 3 liMeliGhT trial of #OCU400 for #retinitispigmentosa, the first and largest gene therapy registrational trial for broad RP patients. Ocugen remains on track to file a rolling BLA in 3Q 2026. #Biotech

Read more: https://t.co/wQIqkq3wuW

[Ocugen @Ocugen]

We support @RareDiseaseDay! At Ocugen, we are committed to advancing our novel modifier gene therapies for rare inherited retinal diseases with significant unmet needs. We stand with patients, families, and the global #raredisease community, today and every day.

[Madpatsy @Madpatsy_]

@tj_t543210987 @Ocugen

[Madpatsy @Madpatsy_]

@tj_t543210987 Sample.
3/1/26 final dose p3
9/1/26 rolling bla
3/1/27 final 12M follow-up full data
4/1/27 full BLA submitted.
9/1/27 BLA Approved.

Fast track is <6 months from full BLA.

[Shankar Musunuri @drsmusunuri]

Great to have Rita join us at a critical time for growth!

[Ocugen @Ocugen]

CSO Arun Upadhyay shares how gene-agnostic modifier therapies could become a leading paradigm for treating major blindness diseases, providing the opportunity to expand patient access for IRDs in @Citeline's Scrip Asks…What Does 2026 Hold for Biopharma?🔗https://t.co/e0qs24rS6Q

[Shankar Musunuri @drsmusunuri]

Wonderful news to see Congress pass legislation that reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) program included in the Give Kids a Chance Act! #BIOTechCaucus #GiveKidsaChance

[Ocugen @Ocugen]

Patients join our clinical trials or EAP with a clear goal: to retain or improve vision. @davidalmeidaMD shares how we support patients and how our novel modifier gene therapies aim to address the entire disease with a single, one-time treatment.

📧[email protected]

[U.S. FDA @US_FDA]

Starting February 1, FDA will accept applications for the PreCheck Pilot Program, a program to strengthen domestic pharmaceutical manufacturing. Learn more: https://t.co/s9UFcQDWhF